Real‐World Study of <scp>EGFR</scp>‐<scp>TKI</scp> Rechallenge With Another <scp>TKI</scp> After First‐Line Osimertinib Discontinuation in Patients With <scp>EGFR</scp>‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
EGFR-TKI rechallenge with another TKI is well tolerated in patients with EGFR-mutated NSCLC. Thus, it may be a useful treatment option after first-line osimertinib failure, especially after osimertinib discontinuation due to toxicity.
Authors
- Kohei Uemura
- Kazuma Kishi (ORCID: https://orcid.org/0000-0002-6801-0147)
- Kazunari Tateishi (ORCID: https://orcid.org/0000-0003-4641-640X)
- Kei Sonehara (ORCID: https://orcid.org/0000-0001-9810-4016)
- Go Naka (ORCID: https://orcid.org/0000-0002-3804-0898)
- Kiyotaka Yoh (ORCID: https://orcid.org/0000-0001-6928-357X)
- Kageaki Watanabe (ORCID: https://orcid.org/0000-0002-8420-5606)
- Yukio Hosomi (ORCID: https://orcid.org/0000-0002-3849-5905)
- Kazuhiro Usui (ORCID: https://orcid.org/0000-0002-4492-9327)
- Hideo Kunitoh
- Shu Tamano
Institutions
- Nihon University (JP)
- Toho University (JP)
- Shinshu University (JP)
- NTT Medical Center (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- National Center for Global Health and Medicine (JP)
- Toho University Omori Medical Center (JP)
- Japanese Red Cross Medical Center (JP)
- National Cancer Center Hospital East (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2024-12-07
- DOI
- https://doi.org/10.1111/1759-7714.15507
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- AstraZeneca